These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Severe insulin resistance secondary to insulin antibodies: successful treatment with the immunosuppressant MMF. Segal T; Webb E; Viner R; Pusey C; Wild G; Allgrove J Pediatr Diabetes; 2008 Jun; 9(3 Pt 1):250-4. PubMed ID: 18547238 [TBL] [Abstract][Full Text] [Related]
11. Insulin antibody response to bovine insulin therapy: functional significance among insulin requiring young diabetics in India. Goswami R; Jaleel A; Kochupillai NP Diabetes Res Clin Pract; 2000 Jul; 49(1):7-15. PubMed ID: 10808058 [TBL] [Abstract][Full Text] [Related]
12. Serum leptin concentrations in children with type 1 diabetes mellitus: relationship to body mass index, insulin dose, and glycemic control. Soliman AT; Omar M; Assem HM; Nasr IS; Rizk MM; El Matary W; El Alaily RK Metabolism; 2002 Mar; 51(3):292-6. PubMed ID: 11887162 [TBL] [Abstract][Full Text] [Related]
13. Factors associated with glycemic control in adult type 1 diabetes patients treated with insulin pump therapy. Matejko B; Skupien J; Mrozińska S; Grzanka M; Cyganek K; Kiec-Wilk B; Malecki MT; Klupa T Endocrine; 2015 Feb; 48(1):164-9. PubMed ID: 24798448 [TBL] [Abstract][Full Text] [Related]
14. A1c, glucose variability and hypoglycemia risk in patients with type 1 diabetes. Guelho D; Paiva I; Batista C; Barros L; Carrilho F Minerva Endocrinol; 2014 Jun; 39(2):127-33. PubMed ID: 24736487 [TBL] [Abstract][Full Text] [Related]
15. The influence of insulin antibodies on the pharmacokinetics of NPH insulin in patients with type 1 diabetes treated with human insulin. Peters A; Klose O; Hefty R; Keck F; Kerner W Diabet Med; 1995 Oct; 12(10):925-30. PubMed ID: 8846686 [TBL] [Abstract][Full Text] [Related]
16. [Blood glucose self-monitoring in intensified insulin therapy: acceptance of frequent measurements and effect on quality of diabetic control]. Weitgasser R; Schnöll F; Pretsch I; Gruber U; Sailer S Acta Med Austriaca; 1998; 25(2):61-4. PubMed ID: 9681045 [TBL] [Abstract][Full Text] [Related]
17. [The effect of anti-insulin antibodies and of peptide C residual secretion on the metabolic control of diabetes type 1]. Velasco N; Díaz de Valdés M; Arteaga A; Acosta AM; Pellegrini MR; Foradori A Rev Med Chil; 1990 Jan; 118(1):3-9. PubMed ID: 2152698 [TBL] [Abstract][Full Text] [Related]
18. The importance of HbA1c and glucose variability in patients with type 1 and type 2 diabetes: outcome of continuous glucose monitoring (CGM). Sartore G; Chilelli NC; Burlina S; Di Stefano P; Piarulli F; Fedele D; Mosca A; Lapolla A Acta Diabetol; 2012 Dec; 49 Suppl 1():S153-60. PubMed ID: 22466072 [TBL] [Abstract][Full Text] [Related]
19. Insulin requirement profiles and related factors of insulin pump therapy in patients with type 2 diabetes. Yang X; Deng H; Zhang X; Yang D; Yan J; Yao B; Weng J; Xu W Sci China Life Sci; 2019 Nov; 62(11):1506-1513. PubMed ID: 31197759 [TBL] [Abstract][Full Text] [Related]
20. Association of morning fasting blood glucose variability with insulin antibodies and clinical factors in type 1 diabetes. Yoneda C; Tashima-Horie K; Fukushima S; Saito S; Tanaka S; Haruki T; Ogino J; Suzuki Y; Hashimoto N Endocr J; 2016 Jul; 63(7):603-9. PubMed ID: 27170092 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]